Saturday 17 October 2026 Export BMRA’s income statement to Excel — free account

Biomerica, Inc.

Biomerica, Inc.’s revenue for fiscal 2026 (year ended May 2026) was $4.5 million, down 16.2% from fiscal 2025. In the quarter to May 2026, revenue grew 17.0%, EPS grew 37.8% and free cash flow fell 35.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

1.85 0.03 −1.60%

Follow BMRA

Alert me

Market cap: $8.6M
P/E: 0.0×
Fwd P/E: 11.4×
Dividend yield: —
F-score: 4/9
Altman Z: −12.45
Beneish M: −2.06
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.16

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	5	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 8.63

Revenue 4.45

Net Income (3.77)

Free Cash Flow (3.43)

Net Debt (1.31)

Current Ratio 1.62

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E 11.40

P/S ratio 1.21

P/B ratio 2.05

Past 5Y EPS Growth —

This Y EPS Growth —

Next Y EPS Growth —

Next Y revenue growth 398.22%

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 6.41%

10-year low 10-year high

P/B against its own 10 years 29.19%

10-year low 10-year high

EV/Sales against its own 10 years 11.28%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	2026
Cash	10	4	2	1
Receivables	1	1	1	1
Inventory	2	2	1	2
Other	—	—	—	—
	13	8	5	4

	2023	2024	2025	2026
Payables	1	1	1	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	2	2	2	2

Compound Annual Growth %

	10y	5y	3y
Sales	(1.42%)	(9.16%)	(5.87%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(6.63%)	(22.20%)	(39.24%)

Revenue $m

	Aug	Nov	Feb	May	Year
’26	—	—	—	—	—
’26	1	1	1	1	4
’25	2	2	1	1	5
’24	2	2	1	1	5
’23	2	1	1	1	5
’22	1	5	8	5	19
’21	1	1	4	1	7

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Aug	Nov	Feb	May	Year
’26	—	—	—	—	—
’26	0	(1)	(1)	(1)	(3)
’25	(1)	(1)	(1)	(1)	(4)
’24	(2)	(1)	(2)	(1)	(5)
’23	(2)	(1)	(2)	(1)	(5)
’22	0	1	2	(4)	0
’21	(2)	(1)	(1)	(1)	(5)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Aug	Nov	Feb	May	Year
’26	—	—	—	—	—
’26	0	(1)	(1)	(1)	(3)
’25	(1)	(1)	(1)	(1)	(4)
’24	(2)	(1)	(2)	(1)	(5)
’23	(2)	(1)	(2)	(1)	(6)
’22	0	1	2	(4)	(1)
’21	(2)	(1)	(1)	(1)	(6)

Fiscal quarters ending in the months shown.

EPS $

	Aug	Nov	Feb	May	Year
’26	—	—	—	—	—
’26	0.00	(0.45)	(0.44)	(0.38)	(1.30)
’25	(0.64)	(0.48)	(0.48)	(0.61)	(2.16)
’24	(0.56)	(0.72)	(0.88)	(0.72)	(2.88)
’23	(1.28)	(0.96)	(0.96)	(0.80)	(4.00)
’22	(0.96)	(0.72)	(0.08)	(1.12)	(2.88)
’21	(1.12)	(1.04)	(1.20)	(0.96)	(4.32)

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	15.44	12.80	13.60	16.40	26.40	20.48	5.60	1.92	2.11	1.45	Analyst estimates 2027–2029 Powerpack
	High	35.52	74.56	29.52	187.12	65.20	42.00	28.64	10.80	10.16	2.94
People
People	Employees	39	39	39	45	49	64	62	64	54	50
	Revenue/emp, $m	0.15	0.14	0.13	0.15	0.15	0.29	0.09	0.08	0.10	0.09
Income, $m
Income, $m	Revenue	6	6	5	7	7	19	5	5	5	4
	Gross margin, %	34.91	31.53	24.84	25.97	5.09	15.78	8.35	11.28	9.38	8.13
	EBT	(1)	(1)	(2)	(3)	(7)	(5)	(7)	(6)	(5)	(4)
	EBT margin, %	(15.69)	(25.77)	(45.55)	(39.89)	(103.25)	(23.88)	(132.78)	(109.62)	(93.62)	(84.26)
	Net income	(1)	(1)	(2)	(3)	(7)	(5)	(7)	(6)	(5)	(4)
	Depreciation	0	0	0	0	0	1	0	0	0	0
Per share, $
Per share, $	Revenue	5.56	5.19	4.52	5.27	4.83	11.91	3.02	2.57	2.31	1.53
	Earnings	(0.88)	(1.36)	(2.08)	(1.84)	(4.32)	(2.88)	(4.00)	(2.88)	(2.16)	(1.30)
	Cash flow	(0.69)	(1.10)	(1.95)	(3.38)	(3.52)	(0.30)	(3.09)	(2.55)	(1.67)	(1.17)
	Capex	(0.09)	(0.12)	(0.15)	(0.09)	(0.20)	(0.11)	(0.04)	(0.05)	(0.02)	0.00
	Free cash flow	(0.79)	(1.22)	(2.10)	(3.48)	(3.72)	(0.41)	(3.14)	(2.60)	(1.69)	(1.17)
	Book value	4.31	4.04	3.46	11.18	6.19	5.26	6.63	3.13	1.79	0.90
	Shares, m	1	1	1	1	1	2	2	2	2	3
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	3.60	6.27	3.99	9.65	6.05	2.35	3.63	1.80	1.47	1.54
	P/B	4.64	8.06	5.21	4.55	4.72	5.33	1.65	1.48	1.90	2.62
	EV/Sales	3.38	6.05	3.85	8.35	5.46	2.04	1.81	1.03	1.01	1.25
	EV/FCF	(23.21)	(25.74)	(8.30)	(12.66)	(7.09)	(59.23)	(1.73)	(1.02)	(1.37)	(1.60)
Cash, $m
Cash, $m	Operating cash flow	(1)	(1)	(2)	(4)	(5)	0	(5)	(5)	(4)	(3)
	Capex	0	0	0	0	0	0	0	0	0	0
	Free cash flow	(1)	(1)	(2)	(4)	(6)	(1)	(6)	(5)	(4)	(3)
Balance, $m
Balance, $m	Working capital	4	4	3	13	8	7	11	6	3	2
	Total debt	—	—	—	2	2	1	1	—	—	—
	Net debt	(1)	(1)	(1)	(9)	(4)	(6)	(10)	(4)	(2)	(1)
	Shareholders’ equity	4	4	4	14	9	8	12	7	4	3
Returns, %
Returns, %	ROA	(16.91)	(28.63)	(45.72)	(23.79)	(51.21)	(39.07)	(55.29)	(50.43)	(65.44)	(59.43)
	ROIC	(18.28)	(29.67)	(45.78)	(30.74)	(93.23)	(117.68)	(225.16)	(164.37)	(188.20)	(251.51)
	ROE	(18.72)	(33.26)	(57.62)	(29.47)	(63.60)	(51.63)	(71.23)	(65.28)	(92.99)	(112.10)

Negative figures in brackets.

All 10 years →

Fiscal years to May 2026 · latest quarter May 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PETV PetVivo Holdings, Inc.	$12.9M	— (loss-making)	— (loss-making)	+13.48% (above 0%: growing)	n/m	+40.13% (above 0%: growing)	66.14%	(476.54%)	Compare
BTCY Biotricity Inc.	$10.9M	— (loss-making)	— (loss-making)	+10.40% (above 0%: growing)	n/m	+235.83% (above 0%: growing)	82.55%	3.70%	Compare
CTSO Cytosorbents Corporation	$9.7M	— (loss-making)	— (loss-making)	+0.17% (above 0%: growing)	n/m	+64.90% (above 0%: growing)	73.18%	(27.39%)	Compare
NMTC NeuroOne Medical Technologies Corporation	$9.5M	— (loss-making)	— (loss-making)	+16.33% (above 0%: growing)	n/m	+26.91% (above 0%: growing)	59.94%	(122.87%)	Compare
BMRA Biomerica, Inc.	$8.6M	— (loss-making)	11.4×	+16.96% (above 0%: growing)	n/m	−35.05% (below 0%: shrinking)	(7.88%)	(174.77%)
AEMD Aethlon Medical, Inc.	$8.5M	— (loss-making)	— (loss-making)	+335.00% (above 0%: growing)	n/m	−11.13% (below 0%: shrinking)	0.00%	0.00%	Compare
TNON Tenon Medical, Inc.	$7.8M	— (loss-making)	— (loss-making)	+126.77% (above 0%: growing)	n/m	−21.78% (below 0%: shrinking)	63.64%	(262.24%)	Compare
WOK WORK Medical Technology Group LTD	$6.0M	—	—	—	—	−948.94% (below 0%: shrinking)	—	—	Compare
AMIX Autonomix Medical, Inc.	$5.7M	— (loss-making)	—	—	n/m	−36.10% (below 0%: shrinking)	—	0.00%	Compare
Median of peers	$9.0M	—	—	+14.91%	—	+7.89%	64.89%	(27.39%)

All 149 Medical Devices stocks →

Biomerica, Inc. (BMRA) key facts

Concern: Biomerica, Inc.’s revenue for fiscal 2026 (year ended May 2026) was $4.5 million, down 16.2% from fiscal 2025.
Biomerica, Inc. (BMRA) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, BMRA traded at $1.85, a market capitalization of $8.6 million.
Return on equity was −112.1% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −12.45 (distress zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations.